1,385,301 Shares in Lyell Immunopharma, Inc. (NASDAQ:LYEL) Bought by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. purchased a new stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 1,385,301 shares of the company's stock, valued at approximately $887,000. Jacobs Levy Equity Management Inc. owned about 0.47% of Lyell Immunopharma at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Graham Capital Management L.P. bought a new stake in shares of Lyell Immunopharma in the 4th quarter valued at about $33,000. RPO LLC acquired a new stake in shares of Lyell Immunopharma in the fourth quarter valued at approximately $42,000. Wells Fargo & Company MN boosted its stake in shares of Lyell Immunopharma by 27.8% during the 4th quarter. Wells Fargo & Company MN now owns 94,320 shares of the company's stock worth $60,000 after acquiring an additional 20,542 shares during the period. SG Americas Securities LLC lifted its position in Lyell Immunopharma by 102.8% during the fourth quarter. SG Americas Securities LLC now owns 116,748 shares of the company's stock worth $75,000 after acquiring an additional 59,182 shares during the last quarter. Finally, BNP Paribas Financial Markets bought a new position in shares of Lyell Immunopharma during the fourth quarter worth approximately $162,000. Institutional investors and hedge funds own 66.05% of the company's stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a "neutral" rating and set a $1.00 target price on shares of Lyell Immunopharma in a report on Wednesday, April 16th.

Lyell Immunopharma Price Performance

NASDAQ:LYEL traded up $0.01 during trading hours on Tuesday, hitting $0.42. The company's stock had a trading volume of 424,582 shares, compared to its average volume of 1,037,119. Lyell Immunopharma, Inc. has a twelve month low of $0.39 and a twelve month high of $2.85. The stock has a fifty day simple moving average of $0.47 and a 200-day simple moving average of $0.66. The company has a market capitalization of $124.57 million, a P/E ratio of -0.53 and a beta of -0.25.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01. The company had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. On average, equities analysts predict that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Sumant Ramachandra purchased 200,000 shares of the business's stock in a transaction dated Friday, March 21st. The shares were purchased at an average cost of $0.58 per share, with a total value of $116,000.00. Following the completion of the purchase, the director now owns 200,000 shares of the company's stock, valued at $116,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Lynn Seely acquired 175,000 shares of the stock in a transaction dated Friday, March 14th. The stock was purchased at an average cost of $0.61 per share, with a total value of $106,750.00. Following the purchase, the chief executive officer now directly owns 712,500 shares of the company's stock, valued at $434,625. This trade represents a 32.56% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 768,640 shares of company stock valued at $449,508. 25.10% of the stock is currently owned by insiders.

Lyell Immunopharma Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.